|
29 Dec 2020 |
Olatec Therapeutics’ Lead Compound, Dapansutrile, a Selective NLRP3 Inhibitor, Prevents the Inflammatory Response and Restores Cognitive and Behavioral Deficits in a Mouse Model of Alzheimer’s Disease
|
|
29 Dec 2020 |
FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831
|
|
29 Dec 2020 |
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
|
|
29 Dec 2020 |
Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus
|
|
29 Dec 2020 |
Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)
|
|
29 Dec 2020 |
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
|
|
29 Dec 2020 |
European Medicines Agency Validates Bristol Myers Squibb’s Application for Zeposia (ozanimod) for the Treatment of Ulcerative Colitis
|
|
29 Dec 2020 |
LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA
|
|
28 Dec 2020 |
First Subject Dosed with Gannex's FXR Agonist ASC42 in a U.S. Phase I Trial
|
|
24 Dec 2020 |
Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
|
|
23 Dec 2020 |
MODAG Initiates First-in-Patient Phase 1b Trial for Anle138b in Parkinson´s Disease
|
|
23 Dec 2020 |
Neomorph, Inc. Announces $109 Million Series A Financing to Advance Proprietary Protein Degradation Platform and Programs
|
|
23 Dec 2020 |
Cytokinetics Regains European Rights to Omecamtiv Mecarbil
|
|
23 Dec 2020 |
Astellas Reports XOSPATA® (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy
|
|
23 Dec 2020 |
AMO Pharma Announces Initiation of Pivotal REACH-CDM Clinical Trial for AMO-02 in Treatment of Congenital Myotonic Dystrophy
|
|
23 Dec 2020 |
Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation
|
|
22 Dec 2020 |
ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe
|
|
22 Dec 2020 |
VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
|
|
22 Dec 2020 |
Amgen Submits Sotorasib Marketing Authorization Application To The European Medicines Agency
|
|
22 Dec 2020 |
Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Us...
|
|
22 Dec 2020 |
BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva
|
|
20 Dec 2020 |
Novartis receives complete response letter from U.S. FDA for inclisiran
|
|
20 Dec 2020 |
FDA Approves First Adjuvant Therapy for Most Common Type of Lung Cancer
|
|
20 Dec 2020 |
U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML
|
|
19 Dec 2020 |
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
|
